Several studies have reported that the tumor tissue expression of anti-programmed death ligand-1 (PD-L1) may be associated with oncological outcomes after IO therapy for various malignant neoplasms [13,14]; however, the utility of PD-L1 expression as a prognostic factor for mRCC remains controversial [3,4,5]. This evidence concerns the gene CD274 and neoplasm.